| Identification | Back Directory | [Name]
LYSOSTAPHIN | [CAS]
9011-93-2 | [Synonyms]
Ambicin L
LYSOSTAPHIN
EC 3.4.24.75
E.C. 3.4.24.75
Lysostaphin from
LYSOSTAPHIN USP/EP/BP
glycyl-glycine endopeptidase
LYSOSTAPHIN AFFINITY PURIFIED
LYSOSTAPHIN ASEPTICALLY FILLED
lysostaphin from staphylococcus simulans
LYSOSTAPHIN ASEPTICALLY FILLED, BR，1200u/mg
Lysostaphin from Staphylococcus staphylolyticus
lysostaphin from staphylococcus staphy-lolyticus
Native Staphylococcus staphylolyticus Lysostaphin
LYSOSTAPHIN, STAPHYLOCOCCUS SIMULANS,*RE COMBINANT
Lysostaphin from Staphylococcus simulans, Recombinant
LYSOSTAPHIN FROM STAPHYLOCOCCUS STAPHY-L OLYTICUS, ~1 U/MG | [EINECS(EC#)]
812-596-7 | [MDL Number]
MFCD00131556 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [form ]
powder
| [color ]
slightly brown
| [biological source]
microbial (Staphylococcus staphylotyticus) | [Water Solubility ]
water: 2.00-2.10mg/mL, clear to slightly hazy, colorless to light yellow | [Merck ]
13,5659 | [Specific Activity]
≥500units/mg protein | [Major Application]
diagnostic assay manufacturing |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS08 | [Signal word ]
Danger | [Hazard statements ]
H334 | [Precautionary statements ]
P261-P284-P501 | [Safety Statements ]
22-24/25 | [WGK Germany ]
3
| [RTECS ]
OL5985000
| [F ]
10-21 | [HS Code ]
3507909090 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Resp. Sens. 1 | [Toxicity]
LD50 (7-day) in mice, rats (mg/kg): 820, 530 i.v. (Zygmunt) |
| Hazard Information | Back Directory | [Uses]
Lysostaphin from Staphylococcus simulans has been used in a study to assess molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus. It has also been used in a study to investigate the sequence analysis of a Staphylococcus aureus gene encoding a peptidoglycan hydrolase activity. | [General Description]
Chemical structure: peptide | [Biochem/physiol Actions]
Lysostaphin is a zinc endopeptidase with a molecular weight of approximately 25 kDa. Because lysostaphin cleaves the polyglycine cross-links in the peptidoglycan layer of the cell wall of Staphylococcus species it has been found useful for cell lysis and also as a potential anti-microbial therapeutic. pH Optimum for activity: ~7.5 | [in vivo]
Lysostaphin (5 mg/kg, intravenous injection, once daily for 3 consecutive days) effectively clears systemic Staphylococcus aureus (MSSA) infections in CF-1 mice[2].
Lysostaphin (50 mg/kg, intravenous injection, single dose) effectively clears Staphylococcus aureus (MSSA and MRSA) infections from the kidneys, spleen, and liver, but is not superior to repeated lower doses[2].
Lysostaphin (1 mg/kg, intravenous injection, once daily for 3 consecutive days) combined with Oxacillin (HY-B0925A) achieves the same antibacterial effect with a lower concentration of Lysostaphin. When combined with Vancomycin, low-dose Lysostaphin (1 mg/kg) similarly shows enhanced efficacy against MRSA[2]. | Animal Model: | Systemic infection model in CF-1 mice induced by methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA)[2] | | Dosage: | 1, 5, 25, 50 mg/kg | | Administration: | Intravenous injection (i.v.), single high-dose administration: 25 mg/kg or 50 mg/kg intravenous injection, single dose; Once daily administration: 1 or 5 mg/kg, once daily for 3 days. | | Result: | Cleared MSSA from the blood and organs of mice (5 mg/kg for 3 days).
Cleared MSSA and MRSA from the kidneys, spleen, and liver (A higher single dose of 50 mg/kg).
Improved effectiveness and allowed reduction of the lysostaphin dose to 1 mg/kg for MRSA infections (Combined with Oxacillin (HY-B0925A) or Vancomycin (HY-B0671)). |
|
|
|